Uniphar (LON:UPR) Given “Buy” Rating at Shore Capital

Uniphar (LON:UPR)‘s stock had its “buy” rating reaffirmed by equities research analysts at Shore Capital in a report released on Tuesday, Marketbeat reports.

Uniphar Price Performance

UPR opened at GBX 219.10 ($2.78) on Tuesday. The stock has a market cap of £682.02 million, a P/E ratio of 15.24 and a beta of 0.75. Uniphar has a 12 month low of GBX 163 ($2.07) and a 12 month high of GBX 256 ($3.25). The company has a quick ratio of 0.60, a current ratio of 0.90 and a debt-to-equity ratio of 119.48. The company has a fifty day simple moving average of GBX 184.78 and a 200 day simple moving average of GBX 197.39.

Uniphar Company Profile

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology
manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.